venBio Partners’s Metacrine, Inc. Common Stock MTCR Stock Holding History

venBio Partners’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,059,123	Closed	-$10.5M	–	10
2021 Q3	$10.5M	Hold	3,059,123	–	–	1.05%	8
2021 Q2	$11.6M	Hold	3,059,123	–	–	1.37%	9
2021 Q1	$19M	Hold	3,059,123	–	–	1.8%	7
2020 Q4	$24M	Hold	3,059,123	–	–	2.12%	6
2020 Q3	$31.2M	Buy	+3,059,123	New	+$31.3M	4.75%	5

Other funds holding MTCR

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

venBio Partners's MTCR Position: Q4 2021 in Review

venBio Partners sold out of Metacrine, Inc. Common Stock (MTCR) in Q4 2021, closing a stake of 3,059,123 shares — an estimated $10.5M sold.

venBio Partners first reported a position in MTCR in Q3 2020 and held it in 5 quarters. The position peaked at $31.2M in Q3 2020. 31 funds tracked by Wall St. Rank hold MTCR as of Q4 2021.

venBio Partners reported no remaining Metacrine, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
venBio Partners sold 3,059,123 Metacrine, Inc. Common Stock shares in Q4 2021, an estimated $10.5M.
venBio Partners first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
venBio Partners's Metacrine, Inc. Common Stock position peaked at $31.2M in Q3 2020.
31 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q4 2021.

Based on venBio Partners's 13F filing for Q4 2021, filed 14 Feb 2022.